Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B

Lucio Boglione; Ilaria De Benedetto; Valentina Dodaro; Marta Chiecchio; Amedeo De Nicolò; Giovanni Di Perri; Antonio D’Avolio

doi:10.1007/s00705-022-05466-y

Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B

Lucio Boglione, Ilaria De Benedetto, Valentina Dodaro, Marta Chiecchio, Amedeo De Nicolò, Giovanni Di Perri, Antonio D’Avolio

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this study was to evaluate plasmatic and urinary therapeutic drug monitoring (TDM) of tenofovir disoproxil fumarate (TDF) in a cohort of patients with chronic hepatitis B (CHB). In 68 enrolled patients, the estimated glomerular filtration rate (eGFR) was 68 mL/min in naive subjects, while in adefovir dipivoxil (ADV)-pretreated patients, it was 55.5 mL/min (p < 0.001). The HBV E genotype was associated with lower TDF levels (β = -0.698, p < 0.001). The urinary TDF concentration was associated with ADV pretreatment (β = 0.829, p < 0.001). Determination of urinary concentrations of TDF may be useful in the clinical management of older CHB patients and those with previous treatment with ADV.

Original language	English
Pages (from-to)	1669-1674
Number of pages	6
Journal	Archives of Virology
Volume	167
Issue number	8
DOIs	https://doi.org/10.1007/s00705-022-05466-y
Publication status	Published - Aug 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00705-022-05466-y

Cite this

@article{a8a15a4a56f94ea8aea349d4f91b6d48,

title = "Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B",

abstract = "The aim of this study was to evaluate plasmatic and urinary therapeutic drug monitoring (TDM) of tenofovir disoproxil fumarate (TDF) in a cohort of patients with chronic hepatitis B (CHB). In 68 enrolled patients, the estimated glomerular filtration rate (eGFR) was 68 mL/min in naive subjects, while in adefovir dipivoxil (ADV)-pretreated patients, it was 55.5 mL/min (p < 0.001). The HBV E genotype was associated with lower TDF levels (β = -0.698, p < 0.001). The urinary TDF concentration was associated with ADV pretreatment (β = 0.829, p < 0.001). Determination of urinary concentrations of TDF may be useful in the clinical management of older CHB patients and those with previous treatment with ADV.",

author = "Lucio Boglione and {De Benedetto}, Ilaria and Valentina Dodaro and Marta Chiecchio and {De Nicol{\`o}}, Amedeo and {Di Perri}, Giovanni and Antonio D{\textquoteright}Avolio",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.",

year = "2022",

month = aug,

doi = "10.1007/s00705-022-05466-y",

language = "English",

volume = "167",

pages = "1669--1674",

journal = "Archives of Virology",

issn = "0304-8608",

publisher = "Springer",

number = "8",

}

TY - JOUR

T1 - Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B

AU - Boglione, Lucio

AU - De Benedetto, Ilaria

AU - Dodaro, Valentina

AU - Chiecchio, Marta

AU - De Nicolò, Amedeo

AU - Di Perri, Giovanni

AU - D’Avolio, Antonio

PY - 2022/8

Y1 - 2022/8

N2 - The aim of this study was to evaluate plasmatic and urinary therapeutic drug monitoring (TDM) of tenofovir disoproxil fumarate (TDF) in a cohort of patients with chronic hepatitis B (CHB). In 68 enrolled patients, the estimated glomerular filtration rate (eGFR) was 68 mL/min in naive subjects, while in adefovir dipivoxil (ADV)-pretreated patients, it was 55.5 mL/min (p < 0.001). The HBV E genotype was associated with lower TDF levels (β = -0.698, p < 0.001). The urinary TDF concentration was associated with ADV pretreatment (β = 0.829, p < 0.001). Determination of urinary concentrations of TDF may be useful in the clinical management of older CHB patients and those with previous treatment with ADV.

AB - The aim of this study was to evaluate plasmatic and urinary therapeutic drug monitoring (TDM) of tenofovir disoproxil fumarate (TDF) in a cohort of patients with chronic hepatitis B (CHB). In 68 enrolled patients, the estimated glomerular filtration rate (eGFR) was 68 mL/min in naive subjects, while in adefovir dipivoxil (ADV)-pretreated patients, it was 55.5 mL/min (p < 0.001). The HBV E genotype was associated with lower TDF levels (β = -0.698, p < 0.001). The urinary TDF concentration was associated with ADV pretreatment (β = 0.829, p < 0.001). Determination of urinary concentrations of TDF may be useful in the clinical management of older CHB patients and those with previous treatment with ADV.

UR - http://www.scopus.com/inward/record.url?scp=85130366611&partnerID=8YFLogxK

U2 - 10.1007/s00705-022-05466-y

DO - 10.1007/s00705-022-05466-y

M3 - Article

SN - 0304-8608

VL - 167

SP - 1669

EP - 1674

JO - Archives of Virology

JF - Archives of Virology

IS - 8

ER -

Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this